InsidersTradesSigma
Solid Biosciences Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Solid Biosciences Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Health Care sector, Solid Biosciences Inc. has published 63 public disclosures. Market capitalisation: €702.9m. The latest transaction was filed on 7 July 2026 (Levée d'options). Among the most active insiders: SMITH IAN F. Every trade is free.
63
Insider Decl.
0
Thresholds
€47m
7 ops.
Buy Volume
€59,500
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Solid Biosciences Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$17.38.
40Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 23,096 of 25,899 companies
22.9
score / 100
Value13
Quality33
FCF yld-14%
Earn yld-16%
EV/EBITDA·
ROE-57%
Gross mgn43%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 July 2026
Declarations63 total
3,440 sharesCommon StockSEC:0001193125-26-297456:0
9,750 sharesCommon StockSEC:0001193125-25-245090:0
2,895 shares@ US$5.9645.8% of flowCommon StockSEC:0001193125-25-245090:1
4,574 sharesCommon StockSEC:0000950170-25-052050:0
1,860 shares@ US$5.335754.2% of flowCommon StockSEC:0000950170-25-038706:0
Ideal exit: 6 Dec 2025 (T+270)
1,000,000 shares@ US$4.0345.8% of flowCommon StockSEC:0000950170-25-025011:0
Ideal exit: 16 Nov 2025 (T+270)
5,000,000 shares@ US$4.0337.8% of flowCommon StockSEC:0001062993-25-003153:0
Ideal exit: 16 Nov 2025 (T+270)
252,545 shares@ US$7.56100.0% of flowCommon Stock, $0.001 par value per shareSEC:0000902664-25-001114:0
Ideal exit: 15 Nov 2025 (T+270)
14,687 sharesCommon StockSEC:0000950170-25-022196:0
10,937 sharesCommon StockSEC:0000950170-25-022203:0
8,125 sharesCommon StockSEC:0000950170-25-022206:0
30,031 sharesCommon StockSEC:0000950170-25-022200:0
7,187 sharesCommon StockSEC:0000950170-25-022201:0
4,861 sharesCommon StockSEC:0000950170-25-022199:0
388 sharesCommon StockSEC:0000950170-25-010625:0
2,994 sharesCommon StockSEC:0000950170-25-003054:0
3,255 sharesCommon StockSEC:0000950170-25-003052:0
28,612 sharesCommon StockSEC:0000950170-24-133360:0
7,239 sharesCommon StockSEC:0000950170-24-133317:0
13,051 sharesCommon StockSEC:0000950170-24-133340:0
11,862 sharesCommon StockSEC:0000950170-24-133369:0
9,750 sharesCommon StockSEC:0000950170-24-116246:0
2,923 shares@ US$6.5054.2% of flowCommon StockSEC:0000950170-24-116246:1
25 of 63 declarations
About Solid Biosciences Inc.
Solid Biosciences Inc. is a biopharmaceutical company focused on developing treatments for rare genetic diseases, particularly Duchenne muscular dystrophy. The company is listed on NASDAQ under the symbol SLDB.